Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Shantha Said To Be Acquisition Target Of GSK, Sanofi

This article was originally published in PharmAsia News

Executive Summary

Two multinational drug makers are reported to be eyeing India's Shantha Biotech as an acquisition. Sources identified the two suitors as U.K.-based GlaxoSmithKline and French drug maker Sanofi-Aventis. Both firms are said to be holding separate talks with the French majority owner, Merieux Alliance, with GSK considered the front-runner. One source said Merieux seeks to sell its entire 80 percent stake in Shantha, valued at more than $196 million. GSK and Sanofi-Aventis said the reports were speculative and Merieux would not comment. (Click here for more

You may also be interested in...

Cipla Claims Success With Advair Trial

Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.

US FDA Requests Ranitidine Removals

FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.

COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen

Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts